SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; for American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 14331444.
  • 2
    Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(suppl 1): S88S100.
  • 3
    Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, et al. Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C [in German]. Z Gastroenterol 2012; 50: 5772.
  • 4
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al.; for ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 24052416.
  • 5
    Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al.; for ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 10141024.
  • 6
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al.; for REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 24172428.
  • 7
    Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; for SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 11951206.
  • 8
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.; for HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 12071217.
  • 9
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 10
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL J r, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 11
    Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients. OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
  • 12
    Rubín A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35: 805812.
  • 13
    Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012; 32(suppl 1): 120128.
  • 14
    Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673684.
  • 15
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 16
    Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 13731383.e1.
  • 17
    Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007; 20: 583590.
  • 18
    Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 5359.
  • 19
    Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669674.
  • 20
    Ponziani FR, Gasbarrini A, Pompili M, Burra P, Fagiuoli S. Management of hepatitis C virus infection recurrence after liver transplantation: an overview. Transplant Proc 2011; 43: 291295.
  • 21
    Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679687.
  • 22
    Schmidt SC, Bahra M, Bayraktar S, Berg T, Schmeding M, Pratschke J, et al. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci 2010; 55: 20632069.
  • 23
    Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents—a potentially lethal cocktail. Hepatology 2011; 54: 35.
  • 24
    Saxena V, Terrault N. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant 2012; 17: 216224.
  • 25
    Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 2027.
  • 26
    Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11: 179185.
  • 27
    Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S, et al. For NRS C020 CUPIC study group. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC) [abstract]. J Hepatol 2012; 56(suppl 2): S4.
  • 28
    Coilly A, Roche B, Botta-Fridlund D, Leroy V, Pageaux PG, Si-Ahmed SN, et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience [abstract]. J Hepatol 2012; 56(suppl 2): S21.
  • 29
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al.; for PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 12921303.
  • 30
    Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13: 2129.
  • 31
    Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, López-Andujar R, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90: 12041209.
  • 32
    Sulkowski MS, Roberts S, Afdhal N, Andreone P, Diago M, Pol S, et al. Ribavirin dose modification in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies [abstract]. J Hepatol 2012; 56(suppl 2): S459S460.